NCT03562832View on ClinicalTrials.gov

Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 20, 2018

Primary Completion Date

April 1, 2024

Study Completion Date

August 1, 2024

Conditions
Metastatic Breast Cancer
Interventions
DRUG

PARP inhibitor 2X-121

600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients

Trial Locations (2)

2730

Herlev and Gentofte Hospital, Herlev Ringvej 75, DK-2730 Herlev, Herlev

7100

Vejle Sygehus, Vejle

Sponsors
All Listed Sponsors
collaborator

Smerud Medical Research International AS

OTHER

collaborator

Danish Breast Cancer Cooperative Group

OTHER

lead

Allarity Therapeutics

INDUSTRY

NCT03562832 - Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP | Biotech Hunter | Biotech Hunter